We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Users running the test should keep an eye out for unexpected clusters of positive Flu B results, which may indicate a tube leak, and repeat tests when two or three analytes are positive, as different results on the repeat test could indicate abnormal PCR cycling. Read More
The European Medicines Agency (EMA) said severe allergies should be included in the list of potential side effects associated with the AstraZeneca/Oxford University vaccine. Read More
Brazil’s health regulator, ANVISA, has given full approval to the AstraZeneca/Oxford University COVID-19 vaccine, following its previous authorization for emergency use. Read More
India’s and South Africa’s proposal to temporarily waive intellectual property rights for COVID-19 vaccines and medicines was stopped once again by opposition from wealthy Western nations, including the U.S., during the World Trade Organization (WTO)’s meeting last week, in a victory for the pharma industry. Read More
The World Health Organization (WHO) issued an Emergency Use Listing on Friday for Johnson & Johnson’s one-shot COVID-19 vaccine — a step that clears the way for the COVAX global vaccine-sharing program to begin distributing the shot to poorer countries hardest hit by the pandemic. Read More
Sanofi Pasteur and Translate Bio are working together on a COVID-19 vaccine candidate that uses messenger-RNA (mRNA) technology and should be easier to store than Moderna’s and Pfizer/ BioNTech’s mRNA-based vaccines. Read More
Novavax said its COVID-19 vaccine demonstrated 96.4 percent efficacy against mild, moderate and severe forms of the original SARS-CoV-2 strain in the final analysis from its phase 3 UK trial. Read More
AstraZeneca (AZ) could be ready to request Emergency Use Authorization (EUA) from the FDA for its COVID-19 vaccine before the end of the month as its U.S. phase 3 trial nears having enough data to adequately assess its efficacy. Read More
Vir Biotechnology and GlaxoSmithKline’s monoclonal antibody for COVID-19 reduced hospitalizations or death from the infection by 85 percent in a phase 3 trial, according to the companies — and they have stopped enrollment in the trial because of the therapy’s “profound efficiency.” Read More
Roche reported that its arthritis drug Actemra (tocilizumab), when paired with the antiviral remdesivir (Veklury) from Gilead Sciences, did not meet the endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia. Read More
Pfizer and BioNTech announced yesterday that their vaccine was 94 percent effective in preventing asymptomatic COVID-19 infection, based on real-world data from Israel, indicating it could greatly reduce transmission from person to person. Read More
RSS
